Oral infliximab nanomedicines for targeted treatment of inflammatory bowel diseases.

Mohan, Lauren J; Daly, Jacqueline S; Ryan, Barbara M; Ramtoola, Zebunnissa

Mohan, Lauren J; Daly, Jacqueline S; Ryan, Barbara M; Ramtoola, Zebunnissa.

Afiliação

Mohan LJ; Division of Biology, Department of Anatomy and Regenerative Medicine, RCSI University of Medicine and Health Sciences, 2, Dublin, Ireland; School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, 2, Dublin, Ireland.
Daly JS; Division of Biology, Department of Anatomy and Regenerative Medicine, RCSI University of Medicine and Health Sciences, 2, Dublin, Ireland.
Ryan BM; Department of Gastroenterology and Clinical Medicine, Tallaght Hospital and Trinity College, Dublin, Ireland.
Ramtoola Z; School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, 2, Dublin, Ireland. Electronic address: zramtoola@rcsi.ie.

Eur J Pharm Sci ; 183: 106379, 2023 Apr 01.

Article em En | MEDLINE | ID: mdl-36646154

Assuntos

Doenças Inflamatórias Intestinais; Nanopartículas; Humanos; Infliximab; Nanomedicina; Qualidade de Vida; Inibidores do Fator de Necrose Tumoral; Mucosa Intestinal; Portadores de Fármacos

Palavras-chave

Caco-2 cells; Inflammatory bowel disease; Infliximab; Nanoparticles; Oral targeted delivery; PLGA-PEG

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Nanopartículas Tipo de estudo: Prognostic_studies Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Eur J Pharm Sci Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google